PharMerica Corp. (NYSE:PMC) shares fell 3.5% on Wednesday . The stock traded as low as $21.45 and last traded at $21.57, with a volume of 84,117 shares. The stock had previously closed at $22.35.

Several brokerages recently weighed in on PMC. TheStreet lowered PharMerica Corp. from a “buy” rating to a “hold” rating in a research report on Monday, May 9th. Zacks Investment Research raised PharMerica Corp. from a “hold” rating to a “strong-buy” rating and set a $30.00 target price on the stock in a research report on Thursday, May 12th. Barrington Research reaffirmed an “outperform” rating and issued a $34.00 target price (up from $30.00) on shares of PharMerica Corp. in a research report on Tuesday, May 10th. Finally, Bank of America Corp. began coverage on PharMerica Corp. in a research report on Tuesday, June 7th. They issued a “buy” rating and a $32.00 target price on the stock. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. PharMerica Corp. presently has a consensus rating of “Hold” and a consensus price target of $31.57.

The company’s 50-day moving average is $25.33 and its 200-day moving average is $24.84. The company has a market cap of $660.50 million and a P/E ratio of 22.18.

PharMerica Corp. (NYSE:PMC) last posted its quarterly earnings data on Tuesday, August 9th. The company reported $0.47 earnings per share for the quarter, hitting the consensus estimate of $0.47. During the same quarter in the previous year, the firm posted $0.48 earnings per share. The firm had revenue of $519.60 million for the quarter, compared to analysts’ expectations of $508.31 million. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. On average, equities research analysts anticipate that PharMerica Corp. will post $2.01 EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of PMC. Airain ltd boosted its position in PharMerica Corp. by 8,998.1% in the fourth quarter. Airain ltd now owns 1,222,061 shares of the company’s stock valued at $14,499,000 after buying an additional 1,208,629 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in PharMerica Corp. by 1.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,579,111 shares of the company’s stock valued at $90,269,000 after buying an additional 41,387 shares during the last quarter. Redwood Investments LLC boosted its position in PharMerica Corp. by 6.3% in the fourth quarter. Redwood Investments LLC now owns 58,400 shares of the company’s stock valued at $2,044,000 after buying an additional 3,444 shares during the last quarter. Trexquant Investment LP boosted its position in PharMerica Corp. by 148.9% in the fourth quarter. Trexquant Investment LP now owns 30,140 shares of the company’s stock valued at $1,055,000 after buying an additional 18,031 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its position in PharMerica Corp. by 3.6% in the fourth quarter. Wells Fargo & Company MN now owns 305,474 shares of the company’s stock valued at $10,692,000 after buying an additional 10,609 shares during the last quarter.

PharMerica Corporation is an institutional pharmacy services company. The Company services healthcare facilities, provides pharmacy management services to hospitals, provides specialty infusion services to patients outside a hospital setting and offers the national oncology pharmacy in the United States.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.